Cargando…
Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506788/ https://www.ncbi.nlm.nih.gov/pubmed/34733959 http://dx.doi.org/10.21037/atm-21-782 |
_version_ | 1784581761677656064 |
---|---|
author | Li, Yang Lin, Yan Shi, Zhixiang Hu, Yuxuan Shao, Taihang Li, Mengyuan Zhu, Jiawen Sun, Lizhou Chang, Feng |
author_facet | Li, Yang Lin, Yan Shi, Zhixiang Hu, Yuxuan Shao, Taihang Li, Mengyuan Zhu, Jiawen Sun, Lizhou Chang, Feng |
author_sort | Li, Yang |
collection | PubMed |
description | BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi Panax notoginseng injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated. METHODS: China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi Panax notoginseng and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications. RESULTS: Twelve papers were all randomized controlled trials (RCTs) in which Sanqi Panax notoginseng injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi Panax notoginseng group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable. CONCLUSIONS: Comparing with Sanqi Panax notoginseng injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi Panax notoginseng injection. |
format | Online Article Text |
id | pubmed-8506788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-85067882021-11-02 Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis Li, Yang Lin, Yan Shi, Zhixiang Hu, Yuxuan Shao, Taihang Li, Mengyuan Zhu, Jiawen Sun, Lizhou Chang, Feng Ann Transl Med Original Article BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi Panax notoginseng injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated. METHODS: China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi Panax notoginseng and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications. RESULTS: Twelve papers were all randomized controlled trials (RCTs) in which Sanqi Panax notoginseng injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi Panax notoginseng group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable. CONCLUSIONS: Comparing with Sanqi Panax notoginseng injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi Panax notoginseng injection. AME Publishing Company 2021-09 /pmc/articles/PMC8506788/ /pubmed/34733959 http://dx.doi.org/10.21037/atm-21-782 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Li, Yang Lin, Yan Shi, Zhixiang Hu, Yuxuan Shao, Taihang Li, Mengyuan Zhu, Jiawen Sun, Lizhou Chang, Feng Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title | Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title_full | Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title_fullStr | Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title_full_unstemmed | Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title_short | Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
title_sort | safflower yellow pigment and sanqi panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506788/ https://www.ncbi.nlm.nih.gov/pubmed/34733959 http://dx.doi.org/10.21037/atm-21-782 |
work_keys_str_mv | AT liyang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT linyan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT shizhixiang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT huyuxuan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT shaotaihang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT limengyuan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT zhujiawen saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT sunlizhou saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis AT changfeng saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis |